Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Hepatorenal Syndrome Treatment Market Growth From $16.09 Billion In 2026 To $21.12 Billion By 2030 At A CAGR Of 7%
The hepatorenal syndrome treatment market has experienced robust expansion in recent years. Projections indicate a rise from $15.17 billion in 2025 to $16.1 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.1%. Historically, this market’s expansion can be linked to factors such as limited awareness of HRS, the absence of uniform treatment protocols, high mortality associated with liver failure, reliance on conventional dialysis methods, and restricted access to advanced therapeutics.
The hepatorenal syndrome treatment market is anticipated to show robust expansion in the coming years. Its size is projected to escalate to $21.12 billion in 2030, driven by a compound annual growth rate (CAGR) of 7.0%. This growth during the forecast period can be attributed to progress in targeted therapies, the adoption of precision medicine methodologies, an expanding healthcare infrastructure, the integration of AI and digital tools for patient monitoring, and increased investment in the development of new drugs. Significant trends expected in the forecast period include the rising occurrence of chronic liver diseases, innovations in renal replacement therapies, customized treatment options for HRS, the expansion of hospital and clinical infrastructure, and a heightened focus on early detection and monitoring.
Get A Free Sample Report With In-Depth Market Insights:
Hepatorenal Syndrome Treatment Market Growth Factors Behind Sustained Expansion
The hepatorenal syndrome treatment market is projected to expand due to an increase in fast-track and novel drug designations. These regulatory pathways are designed to accelerate the development, review, and approval of drugs for serious conditions with unmet medical needs, aiming to deliver innovative therapies to patients more swiftly. This surge in fast-track and novel drug designations is specifically intended to expedite the creation of treatments for hepatorenal syndrome, addressing the urgent demand for effective therapies, potentially improving patient outcomes, and fulfilling unmet medical needs within this condition. For example, in January 2024, the New Drug Therapy Approvals 2023 report from the Center for Drug Evaluation and Research (CDER), a US-based branch of the U.S. Food and Drug Administration (FDA), indicated that CDER approved 55 novel drugs in 2023, with 20 (36%) identified as first-in-class, a notable rise compared to 37 novel drug approvals in 2022. Consequently, the increasing prevalence of fast-track and novel drug designations is significantly driving the growth of the hepatorenal syndrome treatment market.
Hepatorenal Syndrome Treatment Market Segment Landscape And Growth Outlook
The hepatorenal syndrome treatment market covered in this report is segmented –
1) By Type: Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome
2) By Treatment: Therapeutics, Surgical Treatment
3) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Type 1 Hepatorenal Syndrome: Intravenous Albumin, Vasopressors, Dialysis, Liver Transplantation
2) By Type 2 Hepatorenal Syndrome: Albumin Infusion, Midodrine, Octreotide, Liver Transplantation
Hepatorenal Syndrome Treatment Market Industry Trends Fueling Future Revenue Growth
Leading companies in the hepatorenal syndrome treatment market are concentrating on developing novel advancements, such as vasoconstrictive renal-support therapies, to improve kidney function and clinical outcomes for patients facing rapid deterioration linked to advanced liver disease. A vasoconstrictive renal-support therapy is a pharmacological intervention crafted to boost renal perfusion and assist kidney recovery by specifically constricting splanchnic blood vessels and stabilizing circulatory function. For example, in June 2024, Mallinckrodt plc, an Ireland-based specialty pharmaceutical company, presented fresh clinical data on TERLIVAZ, a terlipressin injection approved for hepatorenal syndrome with a swift decline in kidney function. The results demonstrated positive outcomes across several patient subgroups, including enhanced reversal rates of kidney dysfunction and a reduced necessity for renal replacement therapy. This data additionally highlighted the therapy’s importance in tackling a life-threatening complication of advanced liver disease and its capacity to inform earlier diagnosis and more efficient clinical management.
Hepatorenal Syndrome Treatment Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the hepatorenal syndrome treatment market are BioVie Inc., Cumberland Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Orphan Therapeutics LLC, Baxter International Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, Boehringer Ingelheim GmbH, Bayer AG, Gilead Sciences Inc., Pfizer Inc., AstraZeneca PLC, AbbVie Inc., Amgen Inc., F Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd, Astellas Pharma Inc., Kyowa Kirin Co Ltd
View The Full Hepatorenal Syndrome Treatment Market Report:
Hepatorenal Syndrome Treatment Market Geographic Analysis: Where Is Demand Accelerating Fastest?
North America was the largest region in the hepatorenal syndrome treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global hepatorenal syndrome treatment market during the forecast period. The regions covered in the hepatorenal syndrome treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model